A PI3K/mTOR inhibitor, GSK2126458A, given in combination with dabrafenib efficiently counteracted the stimulating effects of a BRAF inhibitor on invasiveness, and VEGF-A and MMP-9 secretion in A375R melanoma cells resistant to darafenib [4]. Here, MMP9 is linked to melanoma.